How to buy Kiniksa Pharmaceuticals stock (KNSA)

Kiniksa Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19.94 – a decrease of 0.6% over the previous week. Kiniksa Pharmaceuticals employs 297 staff and has a trailing 12-month revenue of around $384.1 million.

Our top picks for where to buy Kiniksa Pharmaceuticals stock

Buy Kiniksa Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Kiniksa Pharmaceuticals stock price (NASDAQ: KNSA)

Use our graph to track the performance of KNSA stocks over time.

Kiniksa Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$19.94
52-week range	$16.56 - $28.15
50-day moving average more info button	$23.15
200-day moving average more info button	$21.91
Wall St. target price	$36.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.12

Is it a good time to buy Kiniksa Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kiniksa Pharmaceuticals price performance over time

Historical closes compared with the close of $20.25 from 2024-12-23

1 week (2024-12-18)	0.95%
1 month (2024-11-25)	-7.11%
3 months (2024-09-25)	-15.98%
6 months (2024-06-25)	6.75%

1 year (2023-12-22)	11.02%
2 years (2022-12-23)	30.98%
3 years (2021-12-23)	54.11%
5 years (2019-12-24)	62.52%

Kiniksa Pharmaceuticals financials

Revenue TTM	$384.1 million
Gross profit TTM	$173.2 million
Return on assets TTM	-3.16%
Return on equity TTM	-2.15%
Profit margin	-2.36%
Book value	$6.06
Market Capitalization more info button	$1.4 billion

TTM: trailing 12 months

Kiniksa Pharmaceuticals share dividends

We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.

Have Kiniksa Pharmaceuticals's shares ever split?

Kiniksa Pharmaceuticals's shares were split on 27 June 2024 .

Kiniksa Pharmaceuticals share price volatility

Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $16.56 up to $28.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is 0.348. This would suggest that Kiniksa Pharmaceuticals's shares are less volatile than average (for this exchange).

Kiniksa Pharmaceuticals overview

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom. .

Frequently asked questions

What percentage of Kiniksa Pharmaceuticals is owned by insiders or institutions?
Currently 4.12% of Kiniksa Pharmaceuticals shares are held by insiders and 98.071% by institutions. How many people work for Kiniksa Pharmaceuticals?
Latest data suggests 297 work at Kiniksa Pharmaceuticals. When does the fiscal year end for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals's fiscal year ends in December. Where is Kiniksa Pharmaceuticals based?
Kiniksa Pharmaceuticals's address is: 23 Old Bond Street, London, United Kingdom, WIS 4PZ What is Kiniksa Pharmaceuticals's ISIN number?
Kiniksa Pharmaceuticals's international securities identification number is: BMG5269C1010 What is Kiniksa Pharmaceuticals's CUSIP number?
Kiniksa Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: G5269C101